The recent development in the Exclusion NGAL-patent

By On 10. August 2012 · Leave a Comment · In BioPorto

Our hitherto all time favourite examiner Christine Foster is in immediate danger of losing that Status. The recent development in the Exclusion NGAL-patent shows that the USPTO are still reluctant to grant the patent.

In the case of the ratio patent I think the advantage was/is  that the patent is indeed defining a measured ratio, whereas in the case of the cut-off patent as well as the exclusion patent, the USPTO  the NGAL measurements is just a law of nature…

This is however not a final rejection – but I see this more as a exchange of views – but I think its fair to say that Ms. Foster is not thrilled or convinced 🙂

Exclusion Patent – non final rejection

About Stengaard

BioPorto investor from way back when... I've invested in BioPorto ever since they made their debut on the danish stock exchange, it been a looooong journey with many obstacles. But well worth it all if Bioporto maintains their patent after the proceedings in 2014, and enters into agreements with Global Distributors in 2012 and 2013 If not, then it'll take another xx.years 🙂

Related posts:

  1. The recent development in Triage/Trauma NGAL-patent The USPTO’s Christine Foster ist still not happy with the...
  2. The BioP US patent family, who’s next… Bioporto has filed for more US patents,  all related to...
  3. Applicant Arguments on the USPTO non-final rejection of the “NGAL exclusion patent” application. (Page 1) ...
  4. BioPorto, status of Trauma Patent at USPTO I said to myself  “I wonder what the present status...
  5. BioPorto, status of Trauma Patent at USPTO (II) Last week I gave myself a fright, when browsing the...
 

Leave a Reply

Your email address will not be published. Required fields are marked *

Set your Twitter account name in your settings to use the TwitterBar Section.